References
- Trombetta C, Piccirella S, Perini D, Kistner O, Montomoli E. Emerging influenza strains in the last two decades: a threat of a new pandemic?. Vaccines. 2015; 3:172–85.10.3390/vaccines301017226344952
- World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO. [online] 2016. [cited 2016 May 1]. Available from: http://www.who.int/influenza/human_animal_interface/EN_GIP_20160404cumulativenumberH5N1cases.pdf?ua=1
- Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis. 2010; 201:1644–53.2042322210.1086/652701
- Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebocontrolled, randomized study. J Infect Dis. 2011; 203:1729–38.10.1093/infdis/jir172
- Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One. 2008; 3:e1665.10.1371/journal.pone.000166518301743
- Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007; 370:580–9.10.1016/S0140-6736(07)61297-517707753
- Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults. Vaccine. 2009; 27:7428–35.10.1016/j.vaccine.2009.07.102
- Gillard P, Chu DW, Hwang SJ, Yang PC, Thongcharoen P, Lim FS, et al. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infect Dis. 2014; 14:142.10.1186/1471-2334-14-14224628789
- Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009; 170:679–86.10.1093/aje/kwp23719679750
- Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis. 2008; 8:650–8.10.1016/S1473-3099(08)70232-918922487
- Díez-Domingo J, Baldó JM, Planelles-Catarino MV, Garcés-Sánchez M, Ubeda I, Jubert-Rosich A, et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses. 2015; 9:68–77.2565287310.1111/irv.12295
- Díez-Domingo J, Garcés-Sánchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J. 2010; 29:e35–46.
- Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008; 26:2378–88.1840738210.1016/j.vaccine.2008.02.068
- Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. J Infect Dis. 2015; 211:801–10.2529336810.1093/infdis/jiu548